AKBA Akebia Therapeutics Inc.

8.54
+0.15  (+2%)
Previous Close 8.39
Open 8.37
Price To Book 7
Market Cap 998219404
Shares 116,887,518
Volume 450,210
Short Ratio
Av. Daily Volume 1,094,595

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated in 2019, with top-line results expected in 2020.
Vadadustat - TRILO2GY
Three-times-weekly dosing regimen for vadadustat
Phase 2 trial data due 2019.
Vadadustat - FO2RWARD
Renal anemia
Approved Sept 5, 2014.
Auryxia
Hyperphosphatemia
Phase 3 data due 2Q 2020.
Vadadustat - INNO2VATE
Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)
Phase 3 data due mid-2020.
Vadadustat - PRO2TECT
Non-dialysis patients with anemia related to CKD (NDD-CKD)
sNDA FDA Approval announced November 7, 2017.
Auryxia
Iron deficiency anemia in non-dialysis dependent CKD patients

Latest News

  1. Edited Transcript of AKBA earnings conference call or presentation 18-Mar-19 8:30pm GMT
  2. Akebia Therapeutics (AKBA) Q4 2018 Earnings Conference Call Transcript
  3. Akebia Therapeutics Announces Preliminary Full-Year 2018 Financial Results and Business Highlights
  4. MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
  5. MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?
  6. What Analysts Are Recommending for MannKind and Akebia in March
  7. Why Akebia Therapeutics, Momo, and Switch Jumped Today
  8. Why Akebia Therapeutics Is Soaring Today
  9. The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
  10. Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat in Japanese Patients with Anemia Due to Chronic Kidney Disease
  11. Analysts Estimate Akebia Therapeutics (AKBA) to Report a Decline in Earnings: What to Look Out for
  12. Akebia Therapeutics to Host Fourth Quarter and Full-Year 2018 Investor Update Call and Webcast
  13. Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  14. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Trading At A 29.34% Discount
  15. Seth Klarman Disculoses 4th-Quarter Stock Purchases
  16. Report: Developing Opportunities within T-Mobile US, Noble, Akebia Therapeutics, Vornado Realty Trust, Bio-Rad Laboratories, and Standex International — Future Expectations, Projections Moving into 2019
  17. Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should Know
  18. What Did Akebia Therapeutics, Inc.’s (NASDAQ:AKBA) CEO Take Home Last Year?